Biovica International AB logo

BIOVIC B - Biovica International AB News Story

SEK42.5 0.7  1.7%

Last Trade - 09/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £102.7m
Enterprise Value £89.6m
Revenue £150k
Position in Universe 896th / 1831

BRIEF-Biovica: DiviTumTKA In Early Treatment Resistance Trial

Mon 18th January, 2021 7:03am
Jan 18 (Reuters) - Biovica International AB  BIOVICb.ST :
    * BIOVICA’S DIVITUM®TKA IN EARLY TREATMENT RESISTANCE TRIAL
    * DIVITUM®TKA HAS BEEN SELECTED TO BE INCLUDED IN NEW
PROSPECTIVE
CLINICAL STUDY TIRESIAS
    * AIM IS INVESTIGATING IF DIVITUM TKA CAN BE USED TO
IDENTIFY
EARLY RESISTANCE TO TREATMENT BY A CDK4/6 INHIBITOR IN
COMBINATION WITH AN AROMATASE INHIBITOR IN BREAST CANCER
PATIENTS

Source text for Eikon:  ID:nMFN2PjzG9 
Further company coverage:  BIOVICb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 587696600;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.